SEC Form 4 · accession 0001567619-19-002796
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony G. Quinn
Officer — President & CEO · Director
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 6, 2019 | M | 1,323 | $5.46 | A | 269,000 | D | |
| Common Stock | Feb 6, 2019 | M | 7,433 | $6.31 | A | 276,433 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $5.46 | Feb 6, 2019 | M | 1,323 | D | — | Mar 17, 2026 | Common Stock | 1,323 | 662 | D |
| Stock Option (right to buy)F2 | $6.31 | Feb 6, 2019 | M | 7,433 | D | — | Feb 19, 2028 | Common Stock | 7,433 | 137,517 | D |
Explanation of responses
- F1The stock option vested and became exercisable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
- F2The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.